🔥🐔 BizChicken 🐔🔥

Companies Similar to TG Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Zunsemetinib

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases. It operates through Therapeutics and Contract Research segments, addressing unmet needs with innovative therapies, including treatments for rheumatoid and psoriatic arthritis, atopic dermatitis, autoimmune diseases, inflammatory bowel disease, and certain cancers.

Tags: atopic dermatitis, autoimmune diseases, biopharmaceutical, cancer, contract research, drug development, immune-inflammatory diseases, psoriatic arthritis, rheumatoid arthritis, therapeutics

Symbol: ACRS

Recent Price: $2.48

Industry: Medical - Diagnostics & Research

CEO: Dr. Neal S. Walker D.O., M.D.

Sector: Healthcare

Employees: 86

Address: 640 Lee Road, Wayne, PA 19087

Phone: 484 324 7933

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Cosibelimab

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on acquiring, developing, and commercializing novel treatments for solid tumor cancers. Their lead product candidates include Cosibelimab, a fully-human monoclonal antibody, and other treatments for various cancer targets.

Tags: Antibody, Cancer Treatment, Cosibelimab, EGFR Inhibitor, Immunotherapy, Oncology

Symbol: CKPT

Recent Price: $3.35

Industry: Biotechnology

CEO: Mr. James F. Oliviero III, C.F.A.

Sector: Healthcare

Employees: 23

Address: 95 Sawyer Road, Waltham, MA 02453

Phone: 781 652 4500

Last updated: 2024-12-31

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. logo
Market Cap: High
Employees: Low

therapeutic monoclonal and bispecific antibodies

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.

Tags: biopharmaceutical, bispecific antibodies, cancer treatment, inflammatory diseases, monoclonal antibodies

Symbol: CLDX

Recent Price: $25.12

Industry: Biotechnology

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Employees: 160

Address: Perryville III Building, Hampton, NJ 08827

Phone: 908 200 7500

Leadership

  • Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
  • Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
  • Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Sam Martin, Senior Vice President and Chief Financial Officer
  • Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
  • Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
  • Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
  • Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
  • Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
  • Keith L. Brownlie, Former Partner, Ernst & Young LLP
  • Herbert J. Conrad, Former President, Roche Pharmaceuticals US
  • James J. Marino, J.D., Former Partner, Dechert LLP
  • Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
  • Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
  • Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
  • Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
  • Carl June, M.D.,
  • Michel Nussenzweig, M.D., Ph.D.,
  • Marc E. Rothenberg M.D., Ph.D.,
  • Joseph Schlessinger, Ph.D.,
  • Louis Weiner, M.D.,

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Immunovant, Inc.

Immunovant, Inc. logo
Market Cap: High
Employees: Low

batoclimab

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, monoclonal antibodies

Symbol: IMVT

Recent Price: $23.88

Industry: Biotechnology

CEO: Dr. Peter Salzmann M.B.A., M.D.

Sector: Healthcare

Employees: 207

Address: 320 West 37th Street, New York, NY 10018

Phone: 917 580 3099

Leadership

  • Pete Salzmann, M.D., MBA, Chief Executive Officer
  • Renee Barnett, MBA, Chief Financial Officer
  • Christine Blodgett, Senior Vice President of Human Resources
  • Andy Deig, Senior Vice President Strategic Finance
  • Michael Geffner M.D., MBA, Chief Medical Officer
  • Julie Kirschling, Senior Vice President, Program and Alliance Management
  • Mark Levine, Chief Legal Officer and Corporate Secretary
  • Bill Macias, M.D., Ph.D., Chief Medical Officer
  • Becky Merlina, Senior Vice President, Global Head of Quality
  • Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
  • Jay S. Stout, PhD, Chief Technology Officer
  • Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
  • Chandra Adams, Vice President, Associate General Counsel
  • Maria Alba, M.D., Vice President of Clinical Development
  • Farah Ali, Vice President, Clinical Development
  • Jennifer Ashley, Vice President, Associate General Counsel
  • Annetta Beauregard, Vice President, Regulatory Affairs Strategy
  • Harry Berlanga, MSc., VP, CMC & Distribution Quality
  • Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
  • Scott Forman, MBA, Vice President, Program Management
  • Tom Forman, MBA, Vice President, CMC Project Management
  • Ian Gourley, M.D., Vice President of Clinical Development
  • Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
  • Laci Hasenour, Vice President Marketing, Neurology
  • Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
  • Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
  • Jonathan Janes, MB, Vice President Clinical Development
  • Ant Kidwell, Vice President of IT and Facilities
  • Chedvi Levin-Sister, Vice President of Finance
  • Launi Masterson, Vice President of Clinical Operations
  • Andy Minke, Vice President Program Management
  • Linda McKerral, Vice President, CMC Analytical Sciences
  • Pooja Mehta, Vice President Drug Substance Tech Transfer
  • Regina Mirra, VP, Regulatory Operational Excellence
  • Jennifer Moseley, Vice President of Clinical Operations
  • Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
  • Cassandra Pauyo, Vice President, Data Management
  • Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
  • Lauren Schrier, MBA, Vice President of Marketing
  • Frank Torti, M.D., Chairperson of Board of Directors
  • Andrew Fromkin, Member of Board of Directors
  • Douglas Hughes, Member of Board of Directors
  • George Migausky, Member of Board of Directors
  • Atul Pande, M.D., Member of Board of Directors
  • Eric Venker, M.D., Pharm.D., Member of Board of Directors

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Regulus Therapeutics Inc.

Regulus Therapeutics Inc. logo
Market Cap: Low
Employees: Lowest

RG-012 and RGLS8429

Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.

Tags: biopharmaceutical, clinical stage, drug development, kidney disease, micro RNAs

Symbol: RGLS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Joseph P. Hagan M.B.A.

Sector: Healthcare

Employees: 30

Address: 4224 Campus Point Court, San Diego, CA 92121

Phone: 858 202 6300

Last updated: 2024-12-31

Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Medium

G-MAB antibody library, Sofusa drug delivery technology, ZTlido

Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focusing on developing therapies for various diseases, including cancer and autoimmune diseases, using innovative antibody libraries and drug delivery systems.

Tags: CAR-T therapy, antibody library, autoimmune diseases, biopharmaceutical, cancer therapy, drug delivery

Symbol: SRNE

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Henry H. Ji Ph.D.

Sector: Healthcare

Employees: 949

Address: 4955 Directors Place, San Diego, CA 92121

Phone: 858 203 4100

Last updated: 2024-12-31

TScan Therapeutics, Inc.

TScan Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

T cell receptor-engineered T cell therapies

TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.

Tags: Novartis collaboration, SARS-CoV-2, T cell therapies, biopharmaceutical, cancer treatment, hematologic malignancies, infectious diseases, solid tumors

Symbol: TCRX

Recent Price: $3.00

Industry: Biotechnology

CEO: Dr. Gavin MacBeath Ph.D.

Sector: Healthcare

Employees: 175

Address: 830 Winter Street, Waltham, MA 02451

Phone: 857 399 9500

Leadership

  • Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
  • Katina Dorton, J.D., M.B.A., CFO of Nodthera
  • Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
  • Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
  • Gavin MacBeath, Ph.D., CEO of TSCAN
  • Garry Nicholson, Former President of Pfizer Oncology
  • R. Keith Woods, Former Chief Operating Officer of argenx

Last updated: 2024-12-31

TG Therapeutics, Inc.

TG Therapeutics, Inc. logo
Market Cap: High
Employees: Low

Ublituximab, Umbralisib, Cosibelimab, TG-1701, TG-1801

TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.

Tags: B-cell malignancies, BTK inhibitor, Cosibelimab, Ublituximab, Umbralisib, autoimmune diseases, biopharmaceutical

Symbol: TGTX

Recent Price: $31.45

Industry: Biotechnology

CEO: Mr. Michael S. Weiss Esq.

Sector: Healthcare

Employees: 264

Address: 2 Gansevoort Street, New York, NY 10014

Phone: 212 554 4484

Leadership

  • Michael S. Weiss, Chairman, President, and Chief Executive Officer
  • Sean A. Power, CPA, Chief Financial Officer
  • Adam Waldman, Chief Commercialization Officer

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Unity Biotechnology, Inc.

Unity Biotechnology, Inc. logo
Market Cap: Lowest
Employees: Lowest

UBX1325

Unity Biotechnology, Inc. engages in the research and development of therapeutics aimed at slowing, halting, or reversing diseases of aging with a focus on eye-related conditions.

Tags: aging, biotechnology, drug development, ophthalmology, therapeutics

Symbol: UBX

Recent Price: $0.96

Industry: Biotechnology

CEO: Dr. Anirvan Ghosh Ph.D.

Sector: Healthcare

Employees: 19

Address: 285 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 416 1192

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Arcus Biosciences, Inc.

Arcus Biosciences, Inc. logo
Market Cap: High
Employees: Medium

Cancer Therapies

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing cancer therapies, with a pipeline including products like Etrumadenant, Zimberelimab, and Domvanalimab among others.

Tags: biopharmaceutical, cancer therapies, clinical trials, oncology

Symbol: RCUS

Recent Price: $14.91

Industry: Biotechnology

CEO: Dr. Terry J. Rosen Ph.D.

Sector: Healthcare

Employees: 577

Address: 3928 Point Eden Way, Hayward, CA 94545

Phone: 510 694 6200

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31